NEW
YORK, Nov. 30, 2022 /PRNewswire/
-- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage
biopharmaceutical company focused on the development of precision
medicines for patients with genomically defined cancers, today
announced that Shawn M. Leland,
PharmD, RPh, Founder and Chief Executive Officer of Elevation
Oncology, will participate in a fireside chat at the JMP Securities
Hematology and Oncology Summit on Tuesday,
December 6, 2022 at 11:00 am
ET.
A live webcast and replay of this event will be available on the
Events page of the Company's Investor Relations website at
https://investors.elevationoncology.com/events.
About Elevation Oncology, Inc.
Elevation Oncology is founded on the belief that every patient
living with cancer deserves to know what is driving the growth of
their disease and have access to therapeutics that can stop it. We
aim to make genomic tests actionable by selectively developing
drugs to inhibit the specific alterations that have been identified
as drivers of tumor growth. Together with our peers, we work
towards a future in which each tumor's unique genomic test result
can be matched with a purpose-built precision medicine to enable an
individualized treatment plan for each patient. Our most advanced
candidate, seribantumab, is intended to inhibit tumor growth driven
by NRG1 fusions and is currently being evaluated in the Phase 2
CRESTONE study for patients with solid tumors of any origin that
have an NRG1 gene fusion. Details on the Phase 2 CRESTONE study are
available at www.NRG1fusion.com. Our other product candidate,
EO-3021, is a differentiated, clinical stage antibody drug
conjugate that targets Claudin18.2 and is currently being developed
for the treatment of solid tumors. For more information,
visit www.ElevationOncology.com
Elevation Oncology Investor and Media
Contact
Candice Masse,
978-879-7273
Senior Director, Corporate Communications & Investor
Relations
cmasse@elevationoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-participate-at-the-jmp-securities-hematology-and-oncology-summit-301689754.html
SOURCE Elevation Oncology